The global Hemoglobinopathies market size is expected to be worth around US$ 15.10 billion by 2030, according to a new report by Vision Research Reports.
The global Hemoglobinopathies market size was valued at US$ 7.5 billion in 2020 and is anticipated to grow at a CAGR of 10.9% during forecast period 2021 to 2030.
Increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are expected to propel the market growth over the forecast period. Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.
The development of novel curative technologies, such as CRISPR/Cas9 and hematopoietic transplantation, coupled with a promising pipeline, is expected to propel market growth. Moreover, the presence of regulatory agencies, such as the FDA, which are working toward improving drug approval rate by granting accelerated approval for hemoglobinopathies drugs, is expected to drive the market. For instance, in 2019, the FDA has approved four novel drugs: Reblozyl by Bristol-Myers Squibb Company, Adakveo by Novartis AG, Zynteglo by bluebird bio, Inc., and Oxbryta by Global Blood Therapeutics, Inc. for the treatment of hemoglobinopathies.
Initiatives such as the Sickle Cell Awareness Initiative (SCAI) are working toward educating the people about the disease, which will increase the diagnosis and treatment rate. SCAI also raises funds for individuals affected with sickle cell diseases (SCDs) and provides research funding. Moreover, governments of Middle Eastern and Asian countries provide funds for R&D of hemoglobinopathies treatment. For instance, various programs undertaken by governments, such as thalassemia screening in neonates and providing medicines, are impacting the market growth positively.
The sickle cell disease segment held the largest share of 56.6% in 2020 and is expected to grow at the fastest rate during the forecast period. This is attributed to growing initiatives by biopharmaceutical companies and nonprofit organizations focused on improving access to SCD treatment. Furthermore, sickle cell disease affects around 300,000 newborns annually. An estimated 10% to 40% of the individuals in many African countries are carriers of sickle cell gene, which has resulted in a prevalence of around 2% in these countries. The increasing global disease burden is expected to fuel market growth over the forecast period.
The thalassemia segment is further sub-segmented into alpha-thalassemia and beta-thalassemia. Globally, 5% of the total population are carriers of alpha-thalassemia and around 1.5% of the population have beta-thalassemia traits. India has the maximum number of thalassemia carriers in the world. Moreover, biopharmaceutical companies are actively collaborating with each other to develop novel therapies for treating the disorder. For instance, in December 2017, CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated entered into a partnership to develop and commercialize novel gene-editing treatments for thalassemia using CRISPR/Cas9 technology.
The sickle cell disease diagnosis segment dominated the market and accounted for more than 50.0% share in 2020 owing to high diagnostic rates in North America and Europe. Blood tests are most widely used for the diagnosis of SCD in patients. Moreover, the introduction of newborn baby screening programs for sickle cell disease in countries, such as the U.S., France, and Italy, will drive the segment at the fastest rate. In 2020, a call of action for the newborn screening was signed by many members of the European Parliament and health stakeholders for rare diseases.
The thalassemia diagnosis segment is estimated to grow at a significant rate over the forecast period. The introduction of technologically advanced, rapid, and user-friendly diagnostic tests is driving the segment. In addition, the presence of companies such as Oasis Diagnostics and LabCorp, which provide molecular diagnostic tests based on Multiplex Ligation-dependent Probe Amplification (MLPA) and Polymerase Chain Reaction (PCR) for screening and detection of alpha- and beta-thalassemia, is expected to fuel the segment growth.
The sickle cell disease segment held the largest revenue share of 59.4% in 2020. Extensive research has been carried out to develop novel therapies for treating the disorder, which is contributing to the segment growth. Gene therapy has emerged as a promising treatment option for managing the disorder as it targets the underlying genetic cause of the condition through one-time administration and reduces the need for patients to undertake blood transfusions. Robust product pipeline of gene therapy products, including CTX001 (CRISPR Therapeutics), BIVV003 (Sangamo Therapeutics, Inc. & Bioverativ Inc), and HGB-206 (bluebird bio, Inc), is expected to support segment growth.
Blood transfusion is considered to be the first line of treatment for hemoglobin disorders. The frequency of blood transfusion is higher in thalassemia cases as compared to other hemoglobinopathies. The transfusion is done every 3 to 4 weeks to help maintain the normal level of blood components. However, blood transfusion at frequent intervals increases the risk of acquiring infectious diseases and high blood iron levels. In 2020, the blood supply was interrupted because of a complete lockdown due to COVID-19 in many countries. The overall share of blood transfusion therapy and iron chelation therapy was estimated to decline due to the pandemic in the year 2020.
Bone marrow transplant (BMT) therapy is expected to expand at a significant growth rate over the forecast period. BMT is often used when blood transfusion and other therapies fail. BMT is reported to be effective when performed in the early stages of disease progression. It helps to provide healthy bone marrow to patients who are unable to produce a sufficient number of normal cells. BMT infuses healthy stem cells in the patient’s body to replace the diseased or damaged bone marrow and is increasingly being used to treat severe cases of sickle cell disease and thalassemia.
North America held the largest revenue share of 38.2% in 2020 owing to increasing awareness of hemoglobinopathies among people and improving healthcare facilities. Various organizations spread awareness by conducting different programs. For instance, the Sickle Cell Disease Coalition creates awareness, funds research programs, and provides access to treatment in the U.S. Its membership includes research, public health, and provider organizations, faith-based organizations, industry representatives, foundations, patient groups, and federal agencies. Various initiatives undertaken by research organizations and government bodies to promote research to develop novel therapies for treating hemoglobinopathies are likely to contribute to the market growth in the region.
Moreover, increasing immigration to North America and Europe from high prevalence areas and improving diagnosis and treatment for common and rare genetic diseases, such as thalassemia and sickle cell disease, are some of the factors expected to fuel the market growth in these regions. The prevalence of hemoglobinopathies among migrated people in North America and Europe is high as compared to native people.
Asia Pacific is estimated to exhibit a lucrative growth rate over the forecast period. The presence of a large number of patients suffering from sickle cell disease and thalassemia is expected to propel market growth in the coming years. Favorable government initiatives, which are aimed at improving the standard of care provided to patients affected with hemoglobinopathies, are contributing to the market growth in the region. Due to improved healthcare facilities, the burden of SCD and thalassemia is growing in the region.
Sangamo Therapeutics, Inc.
Global Blood Therapeutics, Inc.
bluebird bio, Inc.
Emmaus Life Sciences Inc.
Prolong Pharmaceuticals, LLC
Sickle Cell Disease
Other Hemoglobin (Hb) Variants
Prenatal Genetic Test
Pre-implantation Genetic Diagnosis
Sickle Cell Disease
Prenatal Genetic Test
Other Hemoglobin (Hb) Variants
Prenatal Genetic Test
Iron Chelation Therapy
Bone Marrow Transplant
Sickle Cell Disease
Bone Marrow Transplant
Other Hemoglobin (Hb) Variants
Iron Chelation Therapy
Bone Marrow Transplant
Middle East & Africa
United Arab Emirates
The Hemoglobinopathies market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Hemoglobinopathies market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Hemoglobinopathies market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hemoglobinopathies market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Hemoglobinopathies market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Hemoglobinopathies capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Hemoglobinopathies by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Hemoglobinopathies market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Hemoglobinopathies market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Hemoglobinopathies market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Hemoglobinopathies industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Hemoglobinopathies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Hemoglobinopathies market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Hemoglobinopathies market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Hemoglobinopathies market. These factors have benefited the growth of the global market for Hemoglobinopathies. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Hemoglobinopathies. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Hemoglobinopathies are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Temperature Controlled Packaging Solutions Market (By Product: Insulated Container, Insulated Shipper; By Application: Food & Beverage, Healthcare, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...
Viral Vectors & Plasmid DNA Manufacturing Market (By Type: Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others; By Workflow: Upstream Processing, Downstream Processing; By Application: Antisense & RNAi, Gene, Cell Therapy, Vaccinology; By End-use: Pharmaceutical and Biopharmaceutical Companies; By Disease: Cancer, Genetic Disorders, Infectious Diseases, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...
Healthcare Facilities Management Market (By Product: Plumbing, Air Conditioning Maintenance, Fire Protection Systems, Mechanical and Electrical Maintenance, Cleaning and Pest Control, Laundry; By Application: Hospital, Ambulatory Service Centers, Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...
Glioblastoma Multiforme Treatment Market (By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy; By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Others; By End-use: Hospitals, Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...
High Pressure Contrast Media Injectors Market (By Product: Injector Systems, Consumables; By Type: Single head injectors, Dual head injectors, Syringeless injectors; By Application: Interventional cardiology, Interventional radiology, Endovascular surgery, Interventional neuroradiology; By End-use: Hospitals, Diagnostic, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...